August 26, 2026 — The global heart pump devices market was valued at USD 4.8 billion in 2025, is estimated at USD 5.5 billion in 2026, and is projected to reach USD 23.2 billion by 2036, expanding at a 15.4% CAGR from 2026 to 2036, according Fact.MR’s Analysis. The forecast represents absolute growth of USD 17.7 billion over the period.

Demand is moving beyond temporary mechanical support toward broader use of durable heart pumps and destination therapy. Fact.MR attributes growth to aging populations, rising cases of ischemic cardiomyopathy linked to diabetes and hypertension, and advances in fully magnetically levitated pumps. Continuous-flow LVADs are also showing improved clinical outcomes, with five-year survival close to 60%, according to the report.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=14331

Clinical and Regulatory Evidence Supports Adoption

Several dated sources cited by Fact.MR support the market's expansion. In October 2022, the Centers for Medicare & Medicaid Services (CMS) revised National Coverage Determination 20.9.1 to expand Medicare destination-therapy coverage to include INTERMACS Profile 3 patients.

In November 2019, the New England Journal of Medicine published results from the MOMENTUM 3 trial. The study reported 86% freedom from disabling stroke or device failure at two years for the relevant HeartMate 3 comparison, as cited by Fact.MR.

Fact.MR also cites a 2024 American Heart Association scientific statement, reporting that 75% of HeartMate 3 patients were discharged within two weeks. In addition, Abbott reported USD 480 million in HeartMate 3 sales in 2024, representing roughly 1,600 implants, according to the report.

Key Numbers

·         Market value, 2025 — USD 4.8 billion

·         Market value, 2026 — USD 5.5 billion

·         Forecast value, 2036 — USD 23.2 billion

·         CAGR, 2026–2036 — 4%

·         Absolute growth — USD 17.7 billion

·         Implanted devices share, 2026 — 3%

·         LVAD share of VAD segment, 2026 — 1%

·         Hospital share — 2%

Source: Fact.MR analysis.

Segment Breakdown

By type, implanted heart pump devices lead with 69.3% share in 2026. These systems can support patients beyond the hospital setting. Fact.MR says implanted devices have durability ranging from three to 10 years, supporting their use in longer-term mechanical circulatory support.

By product, LVADs account for 70.1% of the VAD segment in 2026. The report links this position to the prevalence of left ventricular dysfunction in advanced heart failure. Temporary Impella systems remain important for short-term stabilization, while total artificial hearts continue to face regulatory limits for permanent use.

By end use, hospitals hold 84.2% share. VAD implantation and ECMO cannulation require specialized operating rooms, cardiac surgery capabilities, and related infrastructure.

Country CAGR Outlook

·         China — 7%

·         United States — 4%

·         United Kingdom — 0%

·         South Korea — 8%

·         Japan — 0%

Source: Fact.MR proprietary forecasting model and primary research.

China represents the fastest growth among the listed markets at 21.7% CAGR, supported by expanding cardiac infrastructure, reimbursement initiatives, and domestic LVAD development. The United States follows at 20.4%, supported by regulatory and reimbursement infrastructure. The United Kingdom, South Korea, and Japan are forecast to grow at 20.0%, 19.8%, and 18.0%, respectively.

Competitive Landscape

The market is concentrated in durable implanted LVADs. Abbott Laboratories leads the U.S. durable LVAD market with HeartMate 3 following Medtronic's HVAD withdrawal. ABIOMED, Inc., now under Johnson & Johnson, leads the temporary percutaneous segment with Impella systems. Other companies profiled by Fact.MR include CorWave SA, LivaNova PLC, Berlin Heart GmbH, SynCardia Systems LLC, Jarvik Heart, Inc., BiVACOR Inc., and Medtronic plc.

Fact.MR does not disclose individual company market-share percentages on the supplied page, so no company share is assigned here. The disclosed segment shares are 69.3% for implanted devices, 70.1% for LVADs within the VAD segment, and 84.2% for hospitals.

Analyst View

Shambhu Nath Jha, Principal Consultant at Fact.MR, states that regulatory movement toward destination therapy is reshaping commercial strategy, while device miniaturization and full magnetic levitation technologies are expanding the addressable patient population toward earlier-stage candidates.

Frequently Asked Questions

How large is the heart pump devices market in 2025?
Fact.MR valued the market at USD 4.8 billion in 2025.

What will the heart pump devices market be worth in 2036?
The market is projected to reach USD 23.2 billion by 2036.

What is the CAGR of the heart pump devices market?
Fact.MR forecasts a 15.4% CAGR from 2026 to 2036.

Which heart pump device segment leads the market?
Implanted heart pump devices hold the largest type share at 69.3% in 2026.

Which country has the fastest forecast growth?
China leads the listed countries at 21.7% CAGR through 2036.

Top Report

https://social.mytamam.com/blogs/33895/Agricultural-Biologicals-Market-to-Hit-USD-25-61-Billion-by

https://net-pals.com/blogs/25579/Agricultural-Biologicals-Market-to-Reach-USD-25-61-Billion-by

https://uddokta64.com/blogs/5562/Agricultural-Biologicals-Market-Set-to-Reach-USD-25-61-Billion

https://acmingle.com/blogs/14553/Agricultural-Biologicals-Market-Projected-to-Reach-USD-25-61-Billion

About Fact.MR

Fact.MR is a market research and consulting firm providing market intelligence, forecasts, competitive analysis, and strategic insights across healthcare, technology, industrial, automotive, consumer, and other sectors. Its research combines primary interviews, secondary research, market modeling, and data validation.